You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Claims for Patent: 8,129,507

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,129,507

Title:	Atopic dermatitis inducer
Abstract:	An atopic dermatitis inducer binding to a human own IgE antibody and activating mast cells and basophiles, which includes a purified human secretion fraction, or an antigenic molecule or an antigenic determinant in the purified fraction, and obtained through the following steps of: filtering a human secretion, removing insoluble matters and collecting the filtrate; mixing the filtrate with a ConA-affinity carrier and collecting the supernatant; and separating a component having a histamine-releasing activity from the supernatant by column chromatography. This inducer is effective in diagnosing and treating human atopic dermatitis.
Inventor(s):	Hide; Michihiro (Hiroshima, JP), Tanaka; Toshihiko (Hiroshima, JP), Tanaka; Akio (Hiroshima, JP), Ishii; Kaori (Hiroshima, JP), Suzuki; Hidenori (Hiroshima, JP)
Assignee:	Shionogi & Co., Ltd. (Osaka, JP)
Application Number:	12/461,368
Patent Claims:	1. A method of purifying a human sweat fraction having basophil activation activity, which comprises: filtering human sweat, removing insoluble matters and collecting the filtrate; mixing the filtrate with a ConA-affinity carrier and collecting the supernatant; fractionating the supernatant by anion exchange chromatography and/or reverse phase column chromatography; and contacting each fraction with basophils and assaying the fractions for basophil histamine releasing activity to obtain a fraction having a histamine-releasing activity, wherein the fraction having a histamine-releasing activity has basophil activation activity, and wherein the fraction having a histamine-releasing activity does not have a basophil histamine-releasing activity after incubation with serum from a subject with atopic dermatitis but retains a basophil histamine-releasing activity after incubation with serum from a subject without atopic dermatitis at 37.degree. C. for 30 minutes. 2. The method of claim 1, wherein the fraction having histamine releasing activity does not have basophil histamine releasing activity after incubation with 0.1 .mu.g/.mu.l trypsin at 37.degree. C. for 16 hours.

Details for Patent 8,129,507

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924	⤷ Try a Trial	2023-07-09
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.